Cantor Fitzgerald reiterates Braze stock rating on AI positioning By Investing.com

Cantor Fitzgerald reiterated an Overweight rating and $38 price target on Braze (BRZE), implying >100% upside from the current $18.88 price, even as the stock is down 41% over the past six months. Stifel cut its target to $40 (maintaining Buy) while Needham reiterated Buy with a $50 target and added Braze to its Conviction List; InvestingPro flags the stock as undervalued and notes analysts expect profitability this year. Cantor cites improving execution (verticalization, regional go-to-market, reduced down-sells, better cash collection), a live AI Decisioning Studio, and the June 2, 2025 Offerfit acquisition (cross-selling not yet started) as catalysts into fiscal 2027.

Analysis

The market is treating positioning around generative AI as a binary win/loss filter, which creates a dispersion opportunity: companies that can productize decisioning as an end-to-end workflow (not just an LLM wrapper) will capture outsized share of incremental wallet from both marketing orgs and embedded data science teams. If Braze can demonstrate measurable ROI per campaign (CPL or incremental revenue per 1k MAUs) across three large customers within 6–12 months, the re-rating should be fast because value accrual flows straight into NRR and gross retention — the two metrics investors pay a premium for in SaaS.

A critical second-order dynamic is compute cost sensitivity. Agentic workflows that increase inference load can compress gross margin unless the vendor shifts to hybrid inference, customer-billed compute, or value-based pricing. That creates a sweet spot for companies that embed orchestration and model choice (on-prem vs cloud) — and raises the bar for pure-play model integrators; it also makes strategic partnerships with hyperscalers a lever for either margin support or competitive dependency.

Downside scenarios are concentrated and identifiable: (1) rapid devaluation if customers standardize on open-source stacks and in-source the orchestration layer within 12–24 months; (2) regulatory or privacy incidents tied to automated decisioning that force feature rollbacks; (3) execution slippage on cross-sell integrations that delays expansion bookings by multiple quarters. Each risk is binary and event-driven, so position sizing should be milestone-linked rather than time-decay driven.

Key Decisions for Investors

• Core long (directional): Build a phased long position in BRZE using Jan-2027 LEAPs — buy 60–40 mix of ATM and 25% OTM calls to balance cost and upside. Allocate 1–2% of portfolio; target 2.0–3.0x upside if ARR acceleration and NRR improvement are shown within 12 months; maximum loss = premium paid.
• Event tranche (earnings/metrics): Purchase a 3–6 month call spread ahead of the next quarterly print sized at 0.5% of portfolio to capture a re-rate on outperformance in NRR/NRR retention or GM improvement. Take profits on a 30–50% move; cut at 12% premium decay or a miss on key expansion metrics.
• Paired trade (de-risked relative): Long BRZE / short HUBS sized 0.6x short to long to create a relative exposure to marketing automation share shifts. Time horizon 9–18 months; expect asymmetric payoff if Braze wins wallet share via AI decisioning but hub-based incumbents face slower enterprise integration. Risk: platform-wide multiples compress — cap pair size accordingly.
• Risk-managed hedge: If holding stock outright, buy 3–6 month puts at 10–15% OTM sized to limit downside to ~8–10% of position value across a 6–12 month window to protect versus event risk (privacy/regulatory headlines or broad re-rating).